Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
120,020,745
-
Total 13F shares
-
29,659,351
-
Share change
-
-1,329,599
-
Total reported value
-
$430,705,323
-
Price per share
-
$14.52
-
Number of holders
-
81
-
Value change
-
-$29,549,131
-
Number of buys
-
35
-
Number of sells
-
40
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q3 2018
As of 30 Sep 2018,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
81 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,659,351 shares.
The largest 10 holders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), FRANKLIN RESOURCES INC, FMR LLC, BlackRock Inc., Vivo Capital, LLC, Sofinnova Ventures Inc, Polar Capital LLP, D. E. Shaw & Co., Inc., Vanguard Group Inc, and CITADEL ADVISORS LLC.
This page lists
81
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.